Matthew Wook Chang

USPTO Granted Patents = 10 (Patent Applications = 5)

EPO Patents = 1 (Patent Applications = 4)

Average Co-Inventor Count = 2.6

ph-index = 2

Forward Citations = 7(Granted Patents)

Company Filing History:

7 out of 629

Nanyang Technological University

patents

1 out of 806

National University of Singapore

patents

1 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 2015-2024

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11925667 - Engineered therapeutic probiotic system and method (2024-03-12),

2. 11123380 - Engineered therapeutic probiotic system and method (2021-09-21),

3. 10683521 - Expression construct for sensing cell density and substrate availability and its use in conversion of hydroxycinnamic acids (2020-06-16),

4. 10280427 - Modular synthetic GAL1 promoter and use thereof (2019-05-07),

5. 10113208 - [object Object] (2018-10-30),

6. 9976116 - Programmable synthetic lysis system for controlled release of macromolecules (2018-05-22),

7. 9663800 - Alkane exporter and its use (2017-05-30),

8. 9603877 - Isolated nucleotide molecule and method of sensing and killing of pathogenic microorganism (2017-03-28),

9. 9238715 - Polymerizable composition for ophthalmic and medical use and antimicrobial composition obtained by polymerizing the polymerizable composition (2016-01-19),

10. 9044020 - Isolated nucleotide molecule and method of sensing and killing of pathogenic microorganism (2015-06-02),

Title: The Innovative Contributions of Matthew Wook Chang

Introduction

Matthew Wook Chang is a prominent inventor based in Singapore, known for his groundbreaking work in the field of therapeutic probiotics. With a total of 10 patents to his name, Chang has made significant strides in developing innovative solutions aimed at combating colorectal cancer.

Latest Patents

One of Chang's latest patents is the "Engineered Therapeutic Probiotic System and Method." This invention provides both therapeutic and protective measures against colorectal cancer by utilizing genetically modified gut bacteria in conjunction with an optimized diet high in cruciferous vegetable intake. The claimed system and method maximize the therapeutic value of the cruciferous vegetable diet to eradicate, offset, or prophylactically prevent the onset of colorectal cancer. In this invention, gut bacteria bind specifically to the heparan sulphate proteoglycan on colorectal cancer cells to secrete the enzyme myrosinase. This enzyme transforms host-ingested glucosinolates, which are natural components of cruciferous vegetables, into sulphoraphane, an organic small molecule known for its anti-cancer activity.

Career Highlights

Matthew Wook Chang has had a distinguished career, contributing to significant research and development initiatives. He has worked at esteemed institutions such as Nanyang Technological University and the National University of Singapore, where he has been involved in various innovative projects.

Collaborations

Throughout his career, Chang has collaborated with notable colleagues, including Binbin Chen and Mui Hua Tan. These partnerships have further enhanced his research and development efforts in the field of therapeutic probiotics.

Conclusion

Matthew Wook Chang's contributions to the field of therapeutic probiotics and cancer prevention are noteworthy. His innovative patents and collaborative efforts reflect his commitment to advancing medical science and improving health outcomes.

This text is generated by artificial intelligence and may not be accurate.